Business Wire

AL-SHADOWDRAGON

14.4.2024 18:01:30 CEST | Business Wire | Press release

Share
ShadowDragon™ Releases The OSINT Platform, Horizon®

ShadowDragon™, a provider of ethical open-source intelligence (OSINT) software, unique datasets and APIs, is pleased to announce significant enhancements to its flagship Open-Source Intelligence Investigative platform Horizon®. These updates represent a milestone in the evolution of investigative technology, offering capabilities to streamline investigative processes and uncover valuable insights.

The OSINT Platform encompasses an all-in-one solution for investigations with unparalleled access to publicly available information, including geolocation data, platform monitoring, breach data and the ability to integrate external data streams. This allows for a modern approach to link analysis in one comprehensive toolkit. Horizon® offers access to more than 225 data collection sources, more than 1500 pivot points, and advanced, customizable link analysis capabilities.

Horizon® is accessible with any internet connection and allows users to access critical data and conduct investigations from any device, providing unprecedented flexibility and mobility. Mapping advancements, plotting capability, visual geofencing, and geoestimation allow for different starting points that pinpoint precise locations and uncover valuable insights. Horizon® offers unmatched ease of integration, creating tailored data streams able to solve for any problem set. Horizon® will also enable analysts the ability to work on the go from a tablet, phone, or desktop/laptop.

Horizon®, coupled with ShadowDragon’s SocialNet ® offers a powerful OSINT toolkit that includes more than 225 data collection sources to use for correlating publicly available data, integrated brand monitoring, breach data inquiries, social media information and link analysis capabilities to empower users with a holistic approach to investigations. Users benefit from advanced link analysis capabilities, allowing them to connect the dots and uncover actionable intelligence with ease.

CEO Daniel Clemens said, “Our customers have asked for a unified platform for many years. We are answering their requests with Horizon®, enabling customers to use our platform and data with their existing tools, easily import and export data, while enabling greater focus for complex analysis of data. The Horizon® Platform allows publicly available data to tell the story for the analyst. I am very delighted at what our team has produced and thankful to how our tools help protect many on a global scale.”

“You guys are doing incredible things with SocialNet® and Horizon®. Looking back as a user of Horizon's early release, it has been the coolest privilege to experience the last three years of innovation, watching the platform evolve and morph with every incremental update, and knowing there are always more tweaks still in the works.” - Law Enforcement Customer.

These updates underscore ShadowDragon's commitment to innovation and excellence in the field of investigative technology. By continuously enhancing its OSINT suite with new features, data collection sources and capabilities, ShadowDragon aims to empower investigators with the tools they need to stay ahead of emerging threats and make informed decisions.

Nico Dekens, ShadowDragon Director of Intelligence, said, "This is as close as one can get to having a silver bullet solution that helps solve investigative and analytical needs. This means that no matter what OSINT expertise you have, ShadowDragon's technology will speed up your investigation through an initiative platform. But it is not limited to just the platform and tools, the seasoned team will train you on usage and will support you in getting the most out of your investigative needs. The newly released features and capabilities will make your work future proof and will speed up ANY investigation significantly."

For more information about the ShadowDragon™ suite of OSINT tools and capabilities, such as SocialNet®, OIMonitor®, MalNet®, and Horizon®, click here.

About ShadowDragon

ShadowDragon™ provides comprehensive, cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open source intelligence (OSINT) from over 225 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for Good”.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240413210644/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye